Research programme: ubiquitin modulators - Progenra

Drug Profile

Research programme: ubiquitin modulators - Progenra

Alternative Names: Cbl-b inhibitors - Progenra; Deubiquitylating enzyme inhibitors - Progenra; MuRF1 inhibitors - Progenra; P 013222; P 022077; P 13222; P 5091; P005091; P1001; P1002; P1003; Synoviolin/Hrd1 inhibitors - Progenra; ubiquitin isopeptidase inhibitors - Progenra; USP2 inhibitors - Progenra; USP47 inhibitors - Progenra; USP7 inhibitors - Progenra

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Progenra
  • Class Antineoplastics; Small molecules
  • Mechanism of Action CBLB protein expression inhibitors; Endopeptidase inhibitors; Ubiquitin-protein ligase inhibitors; USP2 protein inhibitors; USP47 protein inhibitors; USP7 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Multiple myeloma; Muscular atrophy; Rheumatoid arthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-myeloma in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Muscle-wasting in USA
  • 04 Nov 2017 No recent reports of development identified for research development in Rheumatoid-arthritis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top